Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?

被引：0
|
作者：
Hertzel C Gerstein
Salim Yusuf
机构：
[1] McMaster University Hamilton,HC Gerstein is the Director of the Division of Endocrinology and Metabolism and S Yusuf is the Director of the Population Research Institute
[2] ON,undefined
[3] Canada.,undefined
来源：
Nature Clinical Practice Endocrinology & Metabolism | 2007年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：798 / 799
页数：1
相关论文
共 50 条
  • [1] Rosiglitazone [Avandia] does not increase the risk of cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus
    [J]. Reactions Weekly, 2008, 1206 (1) : 5 - 5
  • [2] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    [J]. PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [3] Type 2 Diabetes mellitus itself does not increase Mortality or cardiovascular Risk
    Dovjak, Peter
    [J]. ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2018, 51 (08): : 947 - 948
  • [4] Does treatment with rosightazone increase cardiovascular risk of patients with type 2 diabetes melfitus?
    Gerstein, Hertzel C.
    Yusuf, Salim
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (12): : 798 - 799
  • [5] Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus
    Kadoglou, N. P. E.
    Iliadis, F.
    Angelopoulou, N.
    Perrea, D.
    Liapis, C. D.
    Alevizos, M.
    [J]. DIABETIC MEDICINE, 2008, 25 (03) : 333 - 340
  • [6] Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    Tuepker, J
    [J]. CIRCULATION, 2003, 107 (16) : E109 - E109
  • [7] Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    Haffner, SM
    Greenberg, AS
    Weston, WM
    Chen, HZ
    Williams, K
    Freed, MI
    [J]. CIRCULATION, 2002, 106 (06) : 679 - 684
  • [8] Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
    Simo, Rafael
    Rodriguez, Angel
    Caveda, Elena
    [J]. CURRENT DRUG SAFETY, 2010, 5 (03) : 234 - 244
  • [9] DOES ASTHMA INCREASE CARDIOVASCULAR RISK IN TYPE 2 DIABETES?
    Ehrhart, M. D.
    Murray-Krezan, C.
    Qeadan, F.
    Burge, M. R.
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (01) : 310 - 311
  • [10] Does Type 2 Diabetes Mellitus Increase Postoperative Complications in Patients Submitted to Cardiovascular Surgeries?
    Padovani, Caue
    da Costa Arruda, Regiane Maria
    Malosa Sampaio, Luciana Maria
    [J]. BRAZILIAN JOURNAL OF CARDIOVASCULAR SURGERY, 2020, 35 (03) : 249 - 253
12345